PhaseBio Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jonathan Mow
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Great Valley Pkwy Ste 30 Malvern PA United States of America 19355
- IPO Date
- Oct 18, 2018
- CIK
- 0001169245
- Website
- phasebio.com
- Similar Companies
- Business
- PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical company that develops novel therapies for cardiovascular and cardiopulmonary diseases using proprietary elastin-like polypeptide (ELP) technology to enhance drug half-life, stability, and delivery. The company offers lead candidate bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor indicated for uncontrolled major bleeding or urgent surgery in acute coronary syndrome patients; pemziviptadil (PB1046), a once-weekly subcutaneous vasoactive intestinal peptide (VIP) agonist for pulmonary arterial hypertension; and PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension, with additional preclinical candidates leveraging ELP fusion proteins and peptides. Founded in 2002 and headquartered in Malvern, Pennsylvania, PhaseBio operates primarily in the United States with a focus on validated biologics for unmet needs in cardiopulmonary disorders through clinical trials and partnerships. In recent developments, the company entered a co-development agreement with SFJ Pharmaceuticals providing up to $120 million in funding for bentracimab while retaining worldwide commercial rights; acquired assets for PB6440 from Viamet Pharmaceuticals in 2020; secured a supply agreement with BioVectra; and filed for Chapter 11 bankruptcy liquidation on September 30, 2024, resulting in cessation of operations.
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update